Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis

Surgical Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles